ODT Odonate Therapeutics all time low! Buy oportunity?

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.

As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. (businesswire.com)

ODT Odonate Therapeutics MARKET CAP 147.784M
That`s less than its cash balance!

The indicators showed a sell signal just before the selloff.
I know it`s a speculative buy, buy it worth the risk?
What is your opinion?

If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.

Transakcja zakończona: osiągnięto poziom stop:

Odonate said it plans to work with patients in its clinical study to transition to other therapies. After that, the company will shut down at some point in the near future. (fool.com)